Estamos no ar no ! Saiba mais
ícone de CERE

Cerevel Therapeutics Holdings, Inc. Common Stock
CERE

Deslistada

CERE foi retirado da bolsa em 31 de julho de 2024.

Voltar ao ranking
 

Sobre: Cerevel Therapeutics Holdings Inc is dedicated to unraveling the mysteries of the brain to treat neuroscience diseases. The company is tackling neuroscience diseases with a differentiated approach that combines expertise in neurocircuitry with a focus on receptor selectivity. It has a diversified pipeline comprising five clinical-stage investigational therapies and several preclinical compounds with the potential to treat a range of neuroscience diseases, including schizophrenia, epilepsy, Parkinson's disease and substance use disorder. Cerevel Therapeutics is advancing its current research and development programs while exploring new modalities through internal research efforts, external collaborations or potential acquisitions.

Funcionários: 355

Saúde Fabricantes de medicamentos — geral

Notícias

Positivo
Neutro
Negativo
Sentimento 3 meses
Positivo 0%
Neutro 0%
Negativo 0%
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage
LOS ANGELES, CA / ACCESSWIRE / July 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Performing A Scrutiny Into Cerevel Therapeutics Holdings Inc And Proprietors Of CERE Shares Are Welcomed To Engage
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It
LOS ANGELES, CA / ACCESSWIRE / June 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Carrying Out An Inquiry Into Cerevel Therapeutics Holdings Inc And Possessors Of CERE Shares Are Requested To Be Part Of It
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate
LOS ANGELES, CA / ACCESSWIRE / June 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Shares Are Encouraged To Participate
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Stocks Are Encouraged To Participate
LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Holders Of CERE Stocks Are Encouraged To Participate
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / June 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Are Invited To Join
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Owners Of CERE Shares Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Conducting A Probe Into Cerevel Therapeutics Holdings Inc And Owners Of CERE Shares Are Invited To Join
Neutro
Accesswire
há 2 anos
CEREVEL (NASDAQ:CERE) ACQUISITION ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Notified to Contact the Firm
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq:CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
CEREVEL (NASDAQ:CERE) ACQUISITION ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Notified to Contact the Firm
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Embarking On A Probe Into Cerevel Therapeutics Holdings Inc And CERE Shareholders Are Invited To Join
LOS ANGELES, CA / ACCESSWIRE / June 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Embarking On A Probe Into Cerevel Therapeutics Holdings Inc And CERE Shareholders Are Invited To Join
Neutro
GlobeNewsWire
há 2 anos
CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm
NEW YORK, June 25, 2024 (GLOBE NEWSWIRE) -- Leading law firm Bleichmar Fonti & Auld LLP is investigating the merger between Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) and AbbVie, Inc. If you invested in Cerevel Therapeutics you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases/cerevel-therapeutics-holdings-inc-investigation . Claim Details: On December 6, 2023, Cerevel Therapeutics announced that it would be acquired by AbbVie.
CEREVEL (NASDAQ:CERE) STOCK ALERT: Cerevel's $45 Per Share Deal is Being Investigated by BFA Law, Shareholders are Urged to Contact the Firm
Neutro
Accesswire
há 2 anos
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Can Participate
LOS ANGELES, CA / ACCESSWIRE / June 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Cerevel Therapeutics Holdings, Inc. ("Cerevel" or "the Company") (NASDAQ:CERE) for potential breaches of fiduciary duty on the part of its directors and management. The investigation focuses on determining if the Cerevel board breached its fiduciary duties to shareholders.
The Schall Law Firm Is Undertaking An Investigation Into Cerevel Therapeutics Holdings Inc And Shareholders Of CERE Can Participate
Ver ranking de notícias
Gráficos de preços implementados com Lightweight Charts™